Please login to the form below

Not currently logged in
Email:
Password:

ParagonRx appoints ex-FDA medical officer

Dr Stephen Sun joins consultancy as chief medical officer

Burlington, Massachusetts-based risk-benefit consultancy ParagonRx has appointed Dr Stephen Sun as its new chief medical officer.

Dr Sun was formerly a medical officer at US regulator the FDA and in his new role will provide regulatory and strategy advice on the optimal and safe use of new drugs and devices.

He began his pharmaceutical industry career at Organon, working in drug safety and medical knowledge management, before joining Alpharma as director of drug safety.

He was promoted to senior director of medical affairs and then after King Pharmaceuticals' acquisition of Alpharma, Dr Sun served as King's senior director of pharmacovigilance and risk management.

After gaining OTC experience at Reckitt-Benckiser, Dr Sun Sun joined the FDA as a medical officer, serving in the CDER Division of Risk Management and most recently in the Controlled Substances staff.

In his new role at ParagonRx, part of inVentiv Health, he will report directly to ParagonRx president Jeffrey Fetterman.

“The focus today is on enhanced pharmacovigilance, putting preventions in place before any regulatory body requires it,” Fetterman said. “Dr Sun's FDA experience will enrich the guidance we offer clients to assure that active risk management is at the core of developing all new products and services.”

21st August 2013

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....